1. Cheson BD, Martin A: Clinical trials in hairy cell leukemia. Current status and future directions [published erratum appears in Ann Intern Med 107(4):604, 1987 Oct]. Ann Intern Med 106:871-878, 1987.

2. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticu-loendotheliosis. Blood 13:609-630, 1958.

3. Katayama I, Li CY, Yam LT: Histochemical study of acid phosphatase isoenzyme in leukemic reticuloendothelio-sis. Cancer 29:157-164, 1972.

4. Golomb HM, Catovsky D, Golde DW: Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677-683, 1978.

5. Hassan IB, Hagberg H, Sundstrom C: Immunophenotype of hairy-cell leukemia. Eur J Haematol 45:172-176, 1990.

6. Robbins BA, Ellison DJ, Spinosa JC, et al.: Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277-1287, 1993.

7. DelGiudice I, Matutes E, Morilla R, et al.: The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 89:303-308, 2004.

8. Azemar M, Masche A, Schaefer HE, Unger C: Splenic lymphoma with villous lymphocytes—difficulties in differential diagnosis. Onkologie 21:235-239, 1998.

9. Treton D, Valensi F, Troussard X, et al.: Cytokine response of B lymphocytes from splenic lymphoma with villous lymphocytes: correlation with TNF-RII (p75) and CD11c expression. Hematol Cell Ther 38:345-352, 1996.

10. Blasinska-Morawiec M., Robak T, Krykowski E, Hellmann A, Urbanska-Rys H: Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine—a report of three cases. Leuk Lymphoma 25:381-385, 1997.

11. Dunn P, Shih LY, Ho YS, Tien HF: Hairy cell leukemia variant. Acta Haematol 94:105-108, 1995.

12. Wu ML, Kwaan HC, Goolsby CL: Atypical hairy cell leukemia. Arch Pathol Lab Med 124:1710-1713, 2000.

13. Van Norman AS, Nagorney DM, Martin JK, Phyliky RL, Ilstrup DM: Splenectomy for hairy cell leukemia. A clinical review of 63 patients. Cancer 57:644-648, 1986.

14. Jansen J, Hermans J, Remme J, den Ottolander GJ, Cardozo PL: Hairy cell leukaemia. Clinical features and effect of splenectomy. Scand J Haematol 21:60-71, 1978.

15. Jansen J, Hermans J: Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 47:2066-2076, 1981.

16. Bouroncle BA: The history of hairy cell leukemia: characteristics of long-term survivors. Semin Oncol 11:479-485, 1984.

17. Baccarani U, Terrosu G, Donini A, Zaja F, Bresadola F, Baccarani M: Splenectomy in hematology. Current practice and new perspectives. Haematologica 84:431-436, 1999.

18. Walsh RM, Heniford BT: Laparoscopic splenectomy for non-Hodgkin lymphoma. J Surg Oncol 70:116-121, 1999.

19. Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61:349-352, 1983.

20. Mercieca J, Puga M, Matutes E, Moskovic E, Salim S, Catovsky D: Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leuk Lymphoma 14(suppl 1):79-83, 1994.

21. Golomb HM, Jacobs A, Fefer A, et al.: Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 4:900-905, 1986.

22. Lauria F, Forconi F: Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 5:1523-1533, 2004.

23. Chun HG, Leyland-Jones B, Cheson BD: Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9:175-188, 1991.

24. Kantarjian HM, Schachner J, Keating MJ: Fludarabine therapy in hairy cell leukemia. Cancer 67:1291-1293, 1991.

25. Kraut EH, Chun HG: Fludarabine phosphate in refractory hairy cell leukemia. Am J Hematol 37:59-60, 1991.

26. Byrd JC: Concurrent vs sequential rituximab and flu-darabine elicits higher complete response in CLL. Oncol News Int 11:22, 2002.

27. Seymour JF, Kurzrock R, Freireich E J, Estey EH: 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911, 1994.

28. Seymour JF, Talpaz M, Kurzrock R: Response duration and recovery of CD4+ lymphocytes following deoxyco-formycin in interferon-alpha-resistant hairy cell leukemia: 7- year follow-up. Leukemia 11:42-47, 1997.

29. Riley JK, Sliwkowski MX: CD20: a gene in search of a function. Semin Oncol 27:17-24, 2000.

30. Maloney DG, Smith B, Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 29:2-9, 2002.

31. Cordone I, Annino L, Masi S, et al.: Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. J Clin Pathol 48:955-960, 1995.

32. Taji H, Kagami Y, Okada Y, et al.: Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 89:748-756, 1998.

33. Czuczman MS, GrilloLopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999.

34. Coiffier B: Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 29:18-22, 2002.

35. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in b-cell chronic lympho-cytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

J Clin Oncol 19:2153-2164, 2001.

36. Dimopoulos MA, Zervas C, Zomas A, et al.: Treatment of Waldenstrom's macroglobulinemia with rituximab.

J Clin Oncol 20:2327-2333, 2002.

37. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S: Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 18:3875-3877, 2000.

38. Hagberg H: Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol 16:221-222, 1999.

39. Hoffman M, Auerbach L: Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladrib-ine. Br J Haematol 109:900-901, 2000.

40. Sokol L, Agosti SJ: Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am JHematol 75:107-109, 2004.

41. Pollio F, Pocali B, Palmieri S, et al.: Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann Hematol 81:736-738, 2002.

42. Hagberg H, Lundholm L: Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 115:609-611, 2001.

43. Lauria F, Lenoci M, Annino L, et al.: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 86:1046-1050, 2001.

44. Nieva J, Bethel K, Saven A: Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102:810-813, 2003.

45. Thomas DA, O'Brien S, Bueso-Ramos C, et al.: Rituximab in relapsed or refractory hairy cell leukemia. Blood 102:3906-3911, 2003.

46. Cooper N, Stasi R, CunninghamRundles SS, et al.: The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombo-cytopenic purpura. Br J Haematol 125:232-239, 2004.

47. Hensel M, Ho AD: Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol 73:37-40, 2003.

48. Hale G: Biology of the CD52 antigen. CLL Cutting Edge 6:2, 2001.

49. Hale G: The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3:137-143, 2001.

50. Elsner J, Hochstetter R, Spiekermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88:4684-4693, 1996.

51. Hale G, Rye PD, Warford A, Lauder I, Brito-Babapulle A: The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol 23: 189-205, 1993.

52. Quigley MM, Bethel KJ, Sharpe RW, Saven A: CD52 expression in hairy cell leukemia. Am J Hematol 74: 227-230, 2003.

53. Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W: Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 5: 451-452, 2004.

54. Taniguchi T, Minami Y: The IL2/IL-2 receptor system: a current overview. Cell 73:5-8, 1993.

55. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II: Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 126:1398-1403, 1981.

56. Kodaka T, Uchiyama T, Ishikawa T, et al.: Interleukin-2 receptor -chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients. Jpn J Cancer Res 81:902-908, 1990.

57. Yagura H, Tamaki T, Furitsu T, et al.: Demonstration of high-affinity interleukin-2 receptors on B-chronic lym-phocytic leukemia cells: functional and structural characterization. Blut 60:181-186, 1990.

58. Sheibani K, Winberg CD, Velde SVD, Blayney DW, Rappaport H: Distribution of lymphocytes with inter-leukin-2 receptors (TAC antigens) in reactive lympho-proliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas: an immunohistologic study of 300 cases. Am J Pathol 127:27-37, 1987.

59. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394-397, 1989.

60. Kreitman RJ, Chaudhary VK, Waldmann TA, et al.: Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 7:553-562, 1993.

61. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I: Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 83:426-434,

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment